ArticleFrontiers in public health2025
Disease burden and trends in gout for adolescents from 1990 to 2021, with projections to 2050 globally, in East Asia and China: results from the Global Burden of Disease study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gout, a metabolic disorder driven by urate crystal deposition, has been understudied in adolescents, particularly in East Asia and China, where rising incidence aligns with rapid dietary and economic shifts. This study assessed the global, East Asian, and Chinese burden of adolescent gout from 1990 to 2021 and projected trends to 2050. Methods: Using Global Burden of Disease (GBD) 2021 data, we analyzed incidence, prevalence, and disability-adjusted life years (DALYs) among adolescents aged 10-19 years. Age-standardized rates (ASRs) and estimated annual percentage changes (EAPC) were calculated. Autoregressive Integrated Moving Average (ARIMA) models projected future trends, while smoothing splines explored associations between sociodemographic index (SDI) and DALYs. Risk factor contributions were quantified by gender and region. Results: From 1990 to 2021, global ASRs of incidence, prevalence, and DALYs rose annually by 0.26%, reaching 109.1, 653.8, and 20.2 per 100,000 in 2021, respectively. East Asia exhibited steeper increases (0.36-0.37% annually), with Taiwan (Province of China) reporting the highest ASRs (prevalence: 1,054.1; DALYs: 33.2 per 100,000). China saw 17.1-25.1% ASR increases, driven by metabolic risks (36.8%), obesity (31.4%), and kidney dysfunction (7.6%). Females consistently bore higher burdens than males across regions. An M-shaped SDI-DALYs relationship peaked at mid-high development levels (SDI ≈ 0.75). Projections indicated stable global trends but rising incidence and prevalence in East Asia and China by 2050. Discussion: The escalating adolescent gout burden in East Asia and China reflects synergistic effects of obesity, metabolic syndrome, and lifestyle changes. Gender disparities highlight underrecognized risks in females. Sociodemographic transitions initially exacerbate then mitigate gout burden, emphasizing the need for early interventions targeting modifiable risks. Strengthening healthcare infrastructure and gender-specific prevention strategies are critical to curb projected increases in high-risk regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.